NOV 22, 2017
Macular Disease, Retina/Vitreous
In this interview from AAO 2017, Dr. Allen Ho provides an overview on the status of cell-based therapies for retinal disorders. Though many of these agents are in early trial phases, Dr. Ho believes that therapies using stem cell-derived human retinal pigment epithelium cells show the most promise. Additionally, recent improvements in surgical delivery methods appear to improve outcomes while avoiding the adverse effects of previous, more invasive methods.
Relevant Financial Disclosures: Dr. Ho receives grant support from and is an advisor for Johnson & Johnson.